August 2020
-
Smoking Cessation After Cancer Diagnosis: A Neglected Problem
By Jacek Jassem, MD, PhD, and Carolyn Dresler, MD, MPA Posted: August 21, 2020 The world is currently overwhelmed with cases of the novel virus COVID-19 and its devastating death […]
-
Timing of Immune Checkpoint Inhibitors With Respect to Molecular Testing in NSCLC
By Maria Antonia Velez, MD; Nanruoyi Zhou, BA; Brian Henick, MD; and Aaron Lisberg, MD Posted: August 21, 2020 Immune checkpoint inhibitors (CPIs) have revolutionized the treatment of metastatic NSCLC. […]
-
IASLC Journals Share Exciting Milestones on Metrics Journeys
By Joy Curzio Posted: August 21, 2020 The Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer (IASLC), has a 2019 […]
-
Lorlatinib in ROS1-Positive NSCLC: A Review of Recent Data
By Ben Solomon, MBBS, PhD, FRACP Posted: August 21, 2020 ROS1 rearrangements are found in 1% to 2% of patients with NSCLC. They tend to occur in never smokers and […]
-
The Chen-Huang Center for EGFR-Mutant Lung Cancers Represents a ‘Concentrated and Focused Effort’ in Studying Th is Disease Subset
Posted: August 21, 2020 The Chen-Huang Center for EGFR Mutant Lung Cancers, founded at Dana-Farber Cancer Institute earlier this year, is poised to make advances in the study and treatment […]
-
Expanding Efforts Help Address Disparities in Lung Cancer Care
By Kara Nyberg, PhD Posted: August 19, 2020 A multitude of factors contribute to disparities in lung cancer care, including sex, race, education level, income, geographic region, and access to […]
-
A Roadmap to Improving Lung Cancer Care in the Middle East and North Africa
By Abdul Rahman Jazieh, MD, MPH Posted: August 21, 2020 Countries in the Middle East and North Africa region have significant variation in their socioeconomic status, healthcare resources, infrastructure, and […]
-
Brain Metastases in NSCLC: Is Delaying Upfront Radiation a Viable Option?
By Arya Amini, MD, and Chad G. Rusthoven, MD Posted: August 19, 2020 Approximately 10% of patients diagnosed with metastatic NSCLC present with brain metastases, and another 30% develop brain […]
-
Managing lung cancer in the time of COVID-19
Register Now REGISTER NOW for the Medscape Education and IASLC Exclusive Webinar: Immunotherapy and the COVID-19 Pandemic: Addressing Clinical Case Challenges in Lung Cancer on Tuesday, August 11, 2020 @ […]
-
Dr. Harpreet Singh Discusses the Conduct of FDA Clinical Trials During the COVID-19 Pandemic
Harpreet Singh, MD, is director of Division of Oncology 2 at the U.S. Food and Drug Administration (FDA). In the following interview, she discusses the FDA’s response to the COVID-19 […]
View ILCN Archives
Provider Resources